Ye Liu
Shanghai Jiao Tong University(CN)Eastern Institute of Technology, Ningbo
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Chronic Lymphocytic Leukemia Research, Immunotherapy and Immune Responses, Immune Cell Function and Interaction, Lymphoma Diagnosis and Treatment
Most-Cited Works
- → Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase(2019)338 cited
- → IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma(2018)205 cited
- → Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor(2020)95 cited
- → Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study(2022)82 cited
- → Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development(2020)72 cited
- → Tislelizumab uniquely binds to the CC′ loop of PD‐1 with slow‐dissociated rate and complete PD‐L1 blockage(2021)71 cited
- → BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF -Mutated Colorectal Cancers(2015)71 cited
- → BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib(2019)67 cited
- → Sonrotoclax overcomes BCL2 G101V mutation–induced venetoclax resistance in preclinical models of hematologic malignancy(2024)65 cited
- → Abstract 2597: BGB-3111 is a novel and highly selective Bruton's tyrosine kinase (BTK) inhibitor(2015)47 cited